Icon and Parexel partner with B-MS to support clinical dev

By Nick Taylor

- Last updated on GMT

Related tags Clinical trial

Bristol-Myers Squibb (B-MS) has inked deals with Icon and Parexel to support the large volume of clinical development work it expects to perform in coming years.

The deals give B-MS the extra capacity it believes is needed to cope with an expected spike in clinical development. This spike is a consequence of compounds from its “robust internal pipeline​” and “significant inlicensing activity​” passing through clinical trials, said B-MS.

Icon and Parexel will provide the big pharma with “support for full development activities​”, a B-MS spokesperson told Outsourcing-Pharma. B-MS said Icon and Parexel will support its in-house capabilities and capacity with services that “can drive efficiency and cost savings​”.

Services covered by the deals include site management, data handling and monitoring of clinical studies for Phase IIb to IV trials. The spokesperson was unable to say how work will be divided between Icon and Parexel.

B-MS has inked three-year deals with both contract research organisations (CRO). The spokesperson said B-MS is outsourcing to two CROs, as opposed to one, because it believes it is “the best way to channel volume of work while ensuring some level of risk mitigation​”.

Icon and Parexel were chosen “based on their expertise, global reach, governance structure, willingness to partner, as well as their commitment to continuous improvement​”, said the spokesperson.

Over the last ten years, we have forged a strong partnership by working hard to fully understand B-MS’ unique requirements​”, said John Hubbard, Icon group president clinical research services.

Josef von Rickenbach, chairman and CEO of Parexel, said the partnership “is representative of leading models for outsourcing​” and that it can “increase efficiency and create significant value​”.

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Related suppliers

Follow us


View more